00:00America has had 100% tariff in the United States.
00:03The headline is that,
00:05the pharma companies and investors have had 100% tariff in the United States.
00:10The headline came from the United States.
00:12But the story is not so straight,
00:14as the headline is presented in the United States.
00:18Now the question is,
00:20is that America has had 100% tariff in the United States?
00:25Is it Indian medicines now?
00:26In America, the popular market has come from America.
00:28And then Sunfarmer, Dr. Redis, Zippla, Lupin
00:31on the other side?
00:34With the headlines in newspapers,
00:37we will see the headlines.
00:37The banjar, Sunfarmer, Dr. Redis, Zippla, Lupin
00:42and such companies still have so far,
00:44the recommendations have also shown.
00:47So, today we will be the simple,
00:51let's read a whole statement
00:52and the let's say,
00:53is the 100% tariff in the United States.
00:56and why do you think the pharma industry is so bad as affected?
01:01So, look at the US government's government government's government government
01:03has been elected to 2 April 2026.
01:07It has been a lot of patented pharmaceutical products
01:10and its ingredients to be 100% tariff.
01:15It's a legal adhaar, Trade Expansion Act, 1962, Section 232.
01:20In this case, America could have a risk for national security.
01:27But, here is the most important thing.
01:30100% tariff means that
01:33in every country, 100% duty is not 100% duty.
01:38In 23rd, the US government's Bureau of Industry and Security
01:43has given up to 20 jurisdictions for some pharmaceutical products.
01:49What does this mean?
01:53Let us know.
01:54Now, they have several specialty categories,
01:57such as orphan drugs, nuclear medicines, plasma deprived therapies,
02:02fertility drugs, cell therapies, gene therapies, antibody drugs,
02:06and some medical countermeasures.
02:09Now, these products are called eligible products.
02:13And with some pharmaceutical ingredients,
02:160% tariff treatment will be 0% tariff.
02:21So, the headline is 100% tariff.
02:25But, every Indian product does not come to this tariff.
02:28Now, here is an important point.
02:30which is important for you to understand.
02:32Why?
02:32In American Idol, pharmaceutical articles,
02:34finished medicines,
02:36and api's,
02:36and some starting materials,
02:38can be used for starting materials.
02:40But, the inactive ingredients and exemptions
02:43are not used for the same.
02:45And if there aren't any products
02:46in a special category,
02:48then there will be an automatic exemption.
02:52It will be used to not be used to the tariff.
02:53Classification, Origin and Entry Conditions
02:56also be minor.
02:58Now, let's go to the most important
03:01news for this country.
03:03Indian Pharma Exports
03:05of the biggest part is Generic Medicines.
03:08Section 232
03:09of the tariff
03:11generic drugs, biosimilars
03:13and ingredients
03:14to fill out
03:15this is why
03:18the 100% tariff
03:19of the headline is
03:20the direct impact
03:23of the entire pharma exports
03:25of the entire pharma exports
03:26of the entire pharma industry.
03:28In the US pharma story,
03:30there is a very big role in Genrex.
03:34In 2015,
03:35the American prescription drug market
03:38has about 42% of the supply
03:41and in the US pharma exports
03:44has about 95% of Genrex.
03:48If the Genrex
03:50of the 100% tariff
03:51is great,
04:21Kiema importer के लिए 5 टॉलर है तो हंडिट पुसें ड्यूटी के बाद उसकी लानडेट कोस्ट काफी
04:26बढ़ सकती है इसका असर मैनिफाक्चिरर के मार्जिन बायर की कोस्ट और आखिर में जा करके उस दवाई की कीमत
04:33पर पढ़ सकता है
04:34medicine can increase the price. But now, it means that this immediate cost shock has not
04:42come to the pharma sector. Now, Indian generic manufacturers are looking for short-term
04:48route. Sun Pharma, Dr. Redis, Orbindo Pharma, Lupin, Sipla, Zydis, US-focused companies
04:55and companies. The biggest message here is that today's work can be done, but it will
05:01keep the future strategy. Because the risk is not 100% tariff, but it will be more
05:07American policy. Now, in the American policy, Generics and Biosimilars have been kept
05:12in the future. But the Commerce Department will have to review what Generic Imports
05:18policies. So, it will be necessary for the action. And it will be necessary for the
05:23action here. So, it will be necessary for the exemption. It will not be guaranteed for
05:26the exemption. And so, it will be 2028-2022. Trump Phrishasana, Imported Generic
05:34Medicines and Future Tariff have been given to the future tariff. If the years
05:38are given to the high tariff, such as the country, the American market will only be
05:45able to serve the business model to the American market. This can be more
05:48This means that Indian pharma companies can change their strategy from now.
05:53The first change is US manufacturing.
05:57If someone has a manufacturing, packaging, fill-finish facility or local partnership is in America,
06:04then you can manage tariff risk in the coming time.
06:08The second change is product mix.
06:10Plain vanilla, which is very competitive, simple generics by pricing pressure.
06:15This means that companies can focus on complex, generics, injectables, biosimilars and difficult-to-manufacture products.
06:243. API supply chain
06:27Indian pharma companies are in the strength formulation,
06:31but API and other raw materials of global supply chain is also important.
06:36If the American origin, ingredient tracing or local content,
06:41and conditions can increase, then compliance costs will increase.
06:46The fourth change is the market diversification.
06:51America is Indian pharma's most important regulated market.
06:57If companies in Europe, Japan, Latin America, Middle East and other emerging markets
07:03they can also be able to build their own business.
07:05But if they have a diversified market,
07:09they will have a diversified market.
07:10So, different companies will also be different.
07:13If companies are more dependent on US-general exports,
07:16then they are now on its own.
07:18But in the time, the tariff policy will become a big risk.
07:23If companies in US manufacturing are available,
07:26the future tariff risk will be different than their capabilities.
07:32Complex, generics or limited competition products will be different.
07:36The pricing dynamics will be different.
07:39By patent and specialty branded medicines,
07:42they can be exposed more directly in the 100% tariff framework
07:46until they are exemptions or US manufacturing strategy.
07:50And if companies are working in India in the domestic market,
07:55then direct impact can be compared to them,
07:58because they have a diversified market structure.
08:02Now, the biggest question is,
08:03is this 100% tariff in America?
08:05Is this 100% tariff in America right away?
08:08Well, I don't want to say that.
08:10Because in the existing framework,
08:12Indian generic medicines and biosimilars
08:14are available on the 100% tariff.
08:16If you look at the short term,
08:18if you look at Indian generic pharma sector,
08:20the headline is so big,
08:22the actual direct impact is not so big.
08:26But this is also not the risk.
08:28The risk is completely destroyed.
08:30America wants to make its farmer supply chain
08:32more and more domestic.
08:34They want to make a sale.
08:36They don't want to make its farmer supply.
08:38If in the future review,
08:41generics also come from tariffs,
08:42Indian companies,
08:44US manufacturing, acquisitions,
08:46local partnership,
08:47and complex products,
08:49and complex products.
08:51In today's story,
08:52it is not 100% tariff,
08:53but the risk of future policy.
08:56So, these headlines,
08:57you need to see 100% tariff.
08:59It should be more important to future policies.
09:03Short term,
09:04Indian generic pharma sector,
09:08this is the most important thing.
09:11The US policy review,
09:13the US policy review,
09:14the US policy review,
09:16the US policy review,
09:35how quickly we can change our supply chain and US strategy.
